Inspira Technologies is set to unveil its new INSPIRA ART line of medical devices at the Extracorporeal Life Support Organisation Conference in Seattle, US.
The conference is being held between 28 September and 1 October.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Inspira’s new line consists of the INSPIRA ART100 and INSPIRA ART500 devices.
INSPIRA ART100 device is intended for patients undergoing cardiopulmonary bypass procedures.
This device is anticipated to obtain clearance from the US Food and Drug Administration (FDA) in the first half of next year.
The company is presently preparing plans for making the device available in the US.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe INSPIRA ART500 device is being developed to offer acute respiratory support for patients requiring legacy mechanical ventilation.
The device is designed to boost blood oxygen saturation levels within minutes, even as the patient remains awake.
It is expected to provide better treatment for the 20 million patients with severe breathing problems per year.
Recently, the corporation has entered a partnership with US-based Perfusion Solution, which offers advanced medical device platforms, staffing and training to hospitals in the US.
Inspira is focused on the development of blood circulation technology, as well as artificial intelligence-driven monitoring and analytics to deliver patient-centric and data-driven solutions.
The FDA or any other regulatory entity has not yet approved the company’s products. They have also not yet been tested or used on human subjects.
